SLC6A19 and obesity due to melanocortin 4 receptor deficiency: The involvement of the increased levels of FGF21 in protecting against obesity/metabolic syndrome observed in SLC6A19-null mice is supported by numerous recent studies highlighting the therapeutic potential of FGF21 receptor agonists for the treatment of obesity-related diseases such as type 2 diabetes and non-alcoholic fatty liver [69,70].